Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Journal of hematotherapy

Showing results (241-250 of 369) with videos related to

Pageof 37
Sort By:
Journal of Hematotherapy|January 1, 1994
A uniform labeling system for bone marrow and peripheral blood stem cellsE K Jeter, R E Ross
Journal of Hematotherapy|January 1, 1994
A combination of anti-CD15 monoclonal antibody PM-81 and 4-hydroperoxycyclophosphamide augments tumor cytotoxicity while sparing normal progenitor cellsJ Rubin, V Malley, E D Ball
Journal of Hematotherapy|January 1, 1994
Hematopoietic stem cell autografts in support of myeloablative therapy for multiple myelomaB Barlogie, S Jagannath, D Vesole, et al.
Journal of Hematotherapy|October 1, 1995
Primate erythrocyte (E) complement receptor (CR1) as an anchor site for bispecific-based therapies to clear pathogens or autoantibodies safely from the circulationR P Taylor, P J Ferguson
Journal of Hematotherapy|October 1, 1995
Expression of monovalent and bivalent antibody fragments in Escherichia coliS D Grant, P M Cupit, D Learmonth, et al.
Journal of Hematotherapy|October 1, 1995
Preparation of a bispecific F(ab')2 targeted to the human IL-2 receptorJ Y Tso, S L Wang, W Levin, et al.
Journal of Hematotherapy|October 1, 1995
T cell activation and cytokine production in anti-CD3 bispecific antibody therapyR Belani, G J Weiner
Journal of Hematotherapy|October 1, 1995
Properties of bispecific single chain antibodies expressed in Escherichia coliD M Kranz, M Gruber, E R Wilson
Journal of Hematotherapy|October 1, 1995
Clinical experience with CD3 x CD19 bispecific antibodies in patients with B cell malignanciesG C De Gast, A A Van Houten, I A Haagen, et al.
Journal of Hematotherapy|October 1, 1995
A humanized, bispecific immunoadhesin-antibody that retargets CD3+ effectors to kill HIV-1-infected cellsS M Chamow, D Zhang, X Y Tan, et al.
Pageof 37

Showing results (241-250 of 369) with videos related to

Sort By:
Pageof 37
Journal of Hematotherapy|January 1, 1994
A uniform labeling system for bone marrow and peripheral blood stem cellsE K Jeter, R E Ross
Journal of Hematotherapy|January 1, 1994
A combination of anti-CD15 monoclonal antibody PM-81 and 4-hydroperoxycyclophosphamide augments tumor cytotoxicity while sparing normal progenitor cellsJ Rubin, V Malley, E D Ball
Journal of Hematotherapy|January 1, 1994
Hematopoietic stem cell autografts in support of myeloablative therapy for multiple myelomaB Barlogie, S Jagannath, D Vesole, et al.
Journal of Hematotherapy|October 1, 1995
Primate erythrocyte (E) complement receptor (CR1) as an anchor site for bispecific-based therapies to clear pathogens or autoantibodies safely from the circulationR P Taylor, P J Ferguson
Journal of Hematotherapy|October 1, 1995
Expression of monovalent and bivalent antibody fragments in Escherichia coliS D Grant, P M Cupit, D Learmonth, et al.
Journal of Hematotherapy|October 1, 1995
Preparation of a bispecific F(ab')2 targeted to the human IL-2 receptorJ Y Tso, S L Wang, W Levin, et al.
Journal of Hematotherapy|October 1, 1995
T cell activation and cytokine production in anti-CD3 bispecific antibody therapyR Belani, G J Weiner
Journal of Hematotherapy|October 1, 1995
Properties of bispecific single chain antibodies expressed in Escherichia coliD M Kranz, M Gruber, E R Wilson
Journal of Hematotherapy|October 1, 1995
Clinical experience with CD3 x CD19 bispecific antibodies in patients with B cell malignanciesG C De Gast, A A Van Houten, I A Haagen, et al.
Journal of Hematotherapy|October 1, 1995
A humanized, bispecific immunoadhesin-antibody that retargets CD3+ effectors to kill HIV-1-infected cellsS M Chamow, D Zhang, X Y Tan, et al.
Pageof 37